ANNUAL RESULTS 2021

DISCUSSION

Andreas Eckert

CEO & Founder

30 March 2022

A Diversified Global Specialist for Radioactive Applications

ISOTOPE

PRODUCTS

Industry

Radiation

Sources

Services

Trade

Disposal

MEDICAL

Medicine

Medical Devices

Pharmaceuticals

Lab Devices

Engineering

HOLDING

Group Items/

Pipeline

Pentixa

Myelo

Special projects

Engine

+++

180.4 million EUR Revenues in FY 2021

2

34.5 million EUR Net Income

  • 900 Employees (Headcounts)
    19 Sites Worldwide

Results 2021

(EUR million)

Since January 3rd, 2022

Tecnonuclear

3 Buenos Aires

Revenues

180.4

Net Income

34.5

NI/ Sales = 19%

3%

11%

39%

47%

America

Europe

Asia

Middle East & Africa

Slides only for illustration - the spoken word shall be binding

In the Middle of a Rapidly Growing Attractive Market

4

Annual Results Discussion

2021 IN REVIEW

5

Um den Rest dieser Noodl zu lesen, rufen Sie bitte die Originalversion auf, und zwar hier.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Eckert & Ziegler AG published this content on 11 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 November 2022 17:11:06 UTC.